/
•
•
Mounjaro’s blockbuster debut has already sparked a seismic shift across Indian healthcare, diagnostics and pharma. A marked change in consumer behaviour looks imminent.

The stock market has taken note of the company’s ambitious plans in the domestic market. But the path ahead is far from easy.
The hospital chain’s regional as well as insured patient focus has stood it in good stead so far. Its plans to expand could pose challenges though.
The seven-year-old health tech firm has hit a wall with its core surgery business. It is now opening up hospitals.